Skip to content

Allergy, Asthma, and Atopic Eczema in Finland

Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06330974
Acronym
FinnATOPY
Enrollment
2000000
Registered
2024-03-26
Start date
2024-10-31
Completion date
2034-12-31
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergen Immunotherapy, Allergy, Asthma, Asthma in Children, Atopic Dermatitis, Rhinitis, Allergic

Brief summary

The summary is available at --\> https://www.finnatopy.fi/summary

Detailed description

Aims and objectives ---\> https://www.finnatopy.fi/aims-and-objectives Methods ---\> https://www.finnatopy.fi/methods

Interventions

OTHERNo intervention

No intervention

Sponsors

Professor Lauri Lehtimäki
CollaboratorUNKNOWN
Professor Mika Mäkelä
CollaboratorUNKNOWN
Professor Sanna Toppila-Salmi
CollaboratorUNKNOWN
Professor Ilkka Junttila
CollaboratorUNKNOWN
Tampere University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

Inclusion/

Exclusion criteria

---\> https://www.finnatopy.fi/methods

Design outcomes

Primary

MeasureTime frameDescription
Epidemiology of atopic diseases and allergic sensitization profiles in Finland7 yearsIncidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis
Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland7 yearsMorbidity, sick leaves, medication use, costs and expences
Evaluate and improve the current use of diagnostic tests for atopic diseases7 yearsDiagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.
Use and effectiveness of allergen immunotherapy in real world setting7 yearsReal world evidence data using specific cohorts
Direct and indirect costs related to atopic diseases and comorbidities7 yearsAll costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.

Countries

Finland

Contacts

Primary ContactPéter Csonka, MD, PhD
peter.csonka@tuni.fi+358503661103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026